1
|
Riccardi N, Alagna R, Saderi L, Ferrarese M, Castellotti P, Mazzola E, De Lorenzo S, Viggiani P, Udwadia Z, Besozzi G, Cirillo D, Sotgiu G, Codecasa L. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres. BMC Infect Dis 2019; 19:564. [PMID: 31253115 PMCID: PMC6599241 DOI: 10.1186/s12879-019-4211-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2019] [Accepted: 06/21/2019] [Indexed: 02/01/2023] Open
Abstract
Background The increased incidence of drug-resistant TB is a major challenge for effective TB control. Limited therapeutic options and poor treatment outcomes of DR-TB may increase drug-resistance rates. The objective of the study is to retrospectively compare MDR-TB and pre-XDR-TB treatment regimens and outcomes in two large TB reference centres in Italy from January 2000 to January 2015. Methods A retrospective, multicentre study was conducted at the Regional TB Reference Centre Villa Marelli Institute (Milan) and at the Reference Center for MDR-TB and HIV-TB, Eugenio Morelli Hospital (Sondalo). The supra-national Reference Laboratory in Milan performed DST. Inclusion criteria were: age ≥ 18 and culture-confirmed diagnosis of MDR- or pre-XDR TB. Chi-square or Fisher exact test was used to detect differences in the comparison between treatment outcomes, therapeutic regimens, and drug-resistances. Computations were performed with STATA 15. Results A total of 134 patients were selected. Median (IQR) age at admission was 33 (26–41) years and 90 patients (67.2%) were male. Pulmonary TB was diagnosed in 124 (92.5%) patients. MDR- and pre-XDR-TB cases were 91 (67.9%) and 43 (32.1%), respectively. The WHO shorter MDR-TB regimen could have been prescribed in 16/84 (19.1%) patients. Treatment success was not statistically different between MDR- and pre-XDR-TB (81.3% VS. 81.4%; P = 0.99). Mortality in MDR-TB and pre-XDR-TB groups was 4.4 and 9.3%, respectively (P = 0.2). Median duration of treatment was 18 months and a total of 110 different regimens were administered. Exposure to linezolid, meropenem, and amikacin was associated with a better outcome in both groups (P = 0.001, P < 0.001, and P = 0.004, respectively). Conclusions Tailored treatment regimens based on DST results can achieve successful outcomes in patients with pre-XDR-TB.
Collapse
Affiliation(s)
- Niccolò Riccardi
- Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. .,StopTB Italia Onlus, Milan, Italy.
| | - Riccardo Alagna
- StopTB Italia Onlus, Milan, Italy.,Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Laura Saderi
- Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
| | - Maurizio Ferrarese
- StopTB Italia Onlus, Milan, Italy.,E. Morelli Hospital ASST, Reference Centre for HIV-TB, Sondalo, Sondrio, Italy
| | - Paola Castellotti
- StopTB Italia Onlus, Milan, Italy.,E. Morelli Hospital ASST, Reference Centre for HIV-TB, Sondalo, Sondrio, Italy
| | - Ester Mazzola
- E. Morelli Hospital ASST, Reference Centre for HIV-TB, Sondalo, Sondrio, Italy
| | - Saverio De Lorenzo
- E. Morelli Hospital ASST, Reference Center for MDR-TB and HIV-TB, Sondalo, Italy
| | - Pietro Viggiani
- E. Morelli Hospital ASST, Reference Center for MDR-TB and HIV-TB, Sondalo, Italy
| | - Zarir Udwadia
- Department of Pulmonary Medicine, P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra, India
| | | | - Daniela Cirillo
- StopTB Italia Onlus, Milan, Italy.,Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Giovanni Sotgiu
- Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
| | - Luigi Codecasa
- StopTB Italia Onlus, Milan, Italy.,E. Morelli Hospital ASST, Reference Centre for HIV-TB, Sondalo, Sondrio, Italy
| | | |
Collapse
|
2
|
Barakat A, Rufin V, Tran THC. Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept. J Fr Ophtalmol 2018; 41:603-610. [PMID: 30166233 DOI: 10.1016/j.jfo.2018.01.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Revised: 01/03/2018] [Accepted: 01/09/2018] [Indexed: 11/27/2022]
Abstract
PURPOSE To evaluate the 2 year visual and anatomical results of intravitreal aflibercept injection (IAI) in nAMD in treatment-naive eyes in real life using a flexible regimen combining a PRN and modified treat-and-extend (TAE) regimen. PATIENTS AND METHODS This is a retrospective study including 48 eyes of 38 patients with nAMD treated with aflibercept as first line therapy. The modified T&E protocol consisted of a loading phase with 3 monthly IAI followed by an adaptation phase during which patients were monitored and treated as needed at the same visit from week 12 to week 32, then a T&E phase per se, for which the treatment interval was determined based on history of disease recurrence. RESULTS A total of 48 eyes were included. Visual acuity at baseline was 57.3±16 letters. Visual gain was 6±12 letters at 1 year and 5.2±11 letters at 2 years. At the 2-year end point, 94.3% of eyes maintained visual acuity and 71.4% of eyes had ≥70 letters. Reduction of central macular thickness, macular volume and pigment epithelium detachment height was observed after the loading phase, at 1 and 2 years compared to baseline. Complete resolution of fluid was obtained in 78% of eyes after the loading phase, in 68% of eyes at 1 year and in 62.8% of eyes at 2 years. Subfoveal choroidal thickness remained stable during the study. The surface area of the neovascular lesion was reduced at 1 year. The mean number of IAI was 6 IVT (3-11) during the first year and 3.2 IVT (0-13) during the second year. CONCLUSION Aflibercept is effective in real life in treatment-naive eyes at two years. A personalized regimen of IAI for neovascular AMD produced good functional and anatomical outcome over 2 years, with a lower number of injections than in the pivotal studies.
Collapse
Affiliation(s)
- A Barakat
- Ophthalmology department, Lille Catholic hospitals, Lille Catholic University, Saint Vincent de Paul Hospital, boulevard de Belfort, BP387, 59020 Lille cedex, France
| | - V Rufin
- Ophthalmology department, Lille Catholic hospitals, Lille Catholic University, Saint Vincent de Paul Hospital, boulevard de Belfort, BP387, 59020 Lille cedex, France
| | - T H C Tran
- Ophthalmology department, Lille Catholic hospitals, Lille Catholic University, Saint Vincent de Paul Hospital, boulevard de Belfort, BP387, 59020 Lille cedex, France.
| |
Collapse
|